Fig. 4

In vivo therapeutic evaluation of nanocomposites in PC3 tumor-bearing mice. a Schematic illustration of the time schedule for therapeutic treatment. Infrared thermal images (b) and temperature evolution curves (c) at tumor sites during different treatments. d Tumor growth curves during 19 days after different treatments. e The percentages of TAMs (CD45⁺CD11b⁺F4/80⁺) using flow cytometry. f The percentage of M1-like phenotype (CD86^high in CD45⁺CD11b⁺F4/80⁺ cells) and M2-like phenotype (CD163^high in CD45⁺CD11b⁺F4/80⁺) using flow cytometry. g–j Quantification of TAMs, M1-like TAMs, and M2-like TAMs and the ratio of M1/M2 TAMs infiltrated in tumor tissues by flow cytometry (n = 3). Data were presented as mean ± SD. The statistical differences were quantified using Student’s t test (ns, no significance, *p < 0.05, **p < 0.001, ***p < 0.0001)